Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Conclusion: We observed a higher prevalence of abnormal findings using the new allograft fibrosis scoring system – LAfSc. It also showed more specifically the degree and location of fibrosis within hepatic lobule compared to METAVIR. Compared to other LT reports, we observed lower rates of chronic allograft hepatitis and fibrosis at 10 years.

https://doi.org/10.1016/j.aohep.2021.100411

P-48 HEPATITIS DELTA: THE MOST SEVERE OF ALL VIRAL HEPATITIS

Júlia Teixeira Ton1, Ester Teixeira Ton1, Alcione de Oliveira dos Santos2, Juan Miguel Villalobos Salcedo1,2, Mariana Pinheiro Alves Vasconcelos3,4

Introduction: 500,000 to 1.2 million deaths are speculated annually from complications of hepatitis B. The hepatitis Delta virus (HDV) also represents an important public health problem in endemic areas.

Objective: To analyze the clinical and laboratory characteristics at the first consultation of HBV and HBV/HDV patients.

Methods: Retrospective study (2017 and 2018) of 324 records of HBV and HBV/HDV patients at Research Center for Tropical Medicine of Rondônia. Project approved by the Research Ethics Committee. For statistical analysis, SPSS® version 25.0.

Results: A total of 324 patients were included, 302 (93.2%) were HBV and 22 were (6.7%) HBV/HDV. At the first consultation, 16.2% of the HBV showed signs of chronic liver disease, while in the HBV/HDV patients, 59.1% (p < 0.0001). Signs of portal hypertension were present in 7.9% of HBV (splenomegaly in 5.6%) and in 54.3% of HBV/HDV patients (splenomegaly in 45.5%, p < 0.0001). Ascites was seen in almost one third of those co-infected (27.3%). In laboratory analyzes, 6.4% of HBV patients had a total of bilirubin greater than 1.2 mg/dL, among those co-infected (45.5%, p < 0.0001). Albumin was less than 3.5g/dL in 8.4% of the HBV and in 42.8% (p < 0.0001) of the HBV/HDV patients. Alafetoprotein was greater than 10µM/L in 9.7% of the monoinfected and in 18.2% (p: 0.268) of the HBV/HDV patients.

Conclusion: Coinfected patients presented a more serious condition in the first consultation, with signs of portal hypertension and decompensated liver disease, reinforcing HDV as the most severe and rapidly progressive of all viral hepatitis.

https://doi.org/10.1016/j.aohep.2021.100412

P-49 COVID 19-PANDEMIC AND OUTCOMES IN DECOMPENSATE CIRRHOSIS-10 MONTHS REVIEW

Priscila Pollo-Flores, Gabriel Alverca Meyas, Vanessa Rodrigues, Janaísa Moraes de Souza, Pamela Moura Rodrigues Cardoso, Jasmin Torres Leitão, Stephanie Cathren Fenzíola dos Santos da Silva, Lívia Melo Villar

Conclusion: We observed a high prevalence of abnormal findings compared to METAVIR. Compared to other LT reports, we observed lower rates of chronic allograft hepatitis and fibrosis at 10 years.

https://doi.org/10.1016/j.aohep.2021.100412

P-50 PREVALENCE OF HEPATITIS AMONG STUDENTS AND HEALTH PROFESSIONALS AT THE FEDERAL UNIVERSITY OF BAHIA

Jacy Andrade1,4, Lucas Sousa Macêdo1,5,7, Fernanda Bastos1, Marco Antônio Vasconcelos Rêgo1, Robert Eduard Schaer2,5, Roberto Meyer2,5,7, Juçara Magalhães Simões2,5, Songeli Menezes Freire2,5,6,7, Raymundo Parana1,3,7, Maria Isabel Schinoni1,2,3

Objective: To study the prevalence of IgGHAV in college students and health professionals at the Federal University of Bahia.

https://doi.org/10.1016/j.aohep.2021.100413

P-59 COVID 19-PANDEMIC AND OUTCOMES IN DECOMPENSATE CIRRHOSIS-10 MONTHS REVIEW

Fluminense’s Federal University, Oswaldo Cruz’ Institute, Niterói, Rio de Janeiro, Brazil

Background and Aims: Liver abnormalities are frequent in COVID-19 disease, AST and ALT abnormalities are present in about 60% of serious disease patients. However, liver insufficiency and liver mortality were not important concerns. Decompensate cirrhotic patients are a group of high risk for morbidity and mortality. Consequently, we aimed to study cirrhotic patients with at least one complication: ascites, encephalopathy or esophageal varices; to investigate mortality, transplantation and hospitalization due to SARS-Covid-19 infection pandemic.

Methods: Liver unit patients were enrolled after ethical approval and signed consentment term. Combined outcomes during pandemic were analyzed. Participants were submitted to SARS-Cov 2 test by PCR oro/pharyngeal swab. Call phone and medical records were consulted for covid 19 symptoms and outcomes. Survival, transplantation and clinical complications were studied.

Results: Fourthy seven patients were enrolled, 26 followed. Men was 73% of patients and median age was 62.7 years. The cirrhosis etiology in 35% was MAFLD, 32% alcohol, 15% HCV and 18% others. Frequency of COVID-19 infection was 42%, at last 10 months, and three (11%) patients died. Liver-related complications with death were present in 19% of patients without COVID-19 infection. Five patients (19%) were submitted to liver transplantation, without COVID-19 disease.

Conclusion: Although an incident analyzes, our data show high death rate of cirrhotic decompensate patients during COVID-19 pandemic. This population needs a specific approach in order to prevent Covid-19 infection, liver-related mortality and complications during pandemic.

https://doi.org/10.1016/j.aohep.2021.100413